Dr. Mandy Cohen, the director of the Centers for Disease Control and Prevention, reports a rise in Coronavirus cases, with a specific variant, JN.1, appearing to drive the virus’s spread. According to the CDC, JN.1 accounted for approximately 21% of Covid cases in the U.S. as of December 9, marking a significant increase from 8% just two weeks prior.
In a recent phone interview, Dr. Cohen expressed concern over JN.1 becoming the dominant version of the Covid virus, indicating higher transmissibility. Fortunately, she noted that there is no observed increase in the severity of the illness associated with this variant.
Globally, JN.1 is gaining momentum, representing 27% of genetic sequences submitted to the GISAID global virus database in the week ending December 3, up from 10% in the week ending November 19. The World Health Organization (WHO) has declared JN.1 a “variant of interest,” a designation given to variants that drive new cases and may possess genetic changes facilitating increased spread or immunity evasion.
Despite its prevalence, the illness caused by JN.1, a descendant of omicron, does not appear to be more severe than earlier Covid cases. Doctors, however, caution that symptoms may evolve over time, but regular data collection on symptom changes is lacking.
Dr. Molly Fleece, a hospital epidemiologist, notes that JN.1 symptoms, including sore throats and congestion, seem similar to previous variants. While severe cases still exhibit familiar characteristics such as shortness of breath and chest pain, overall Covid symptoms have become milder than in the early stages of the pandemic.
Amidst the holiday season, concerns arise about the ease of JN.1 transmission, especially considering the precedent set by omicron’s rapid spread. The WHO warns of a potential increase in Covid cases during the winter, adding to the burden of respiratory infections.
JN.1’s parent lineage, BA.2.86, features numerous mutations compared to the original omicron, allowing the virus to sidestep existing immunity. The additional mutation in the JN.1 spike protein may enhance its ability to invade cells.
While the WHO asserts that JN.1 is unlikely to pose an added public health risk compared to other variants, updated vaccines targeting a different variant, XBB.1.5, appear effective against JN.1. A preprint study suggests that Moderna and Pfizer’s mRNA shots boost antibody protection against JN.1, but further peer review is needed.
You can also read: Mystery Surrounds Arizona House Fire Claiming 5 Lives, Including 3 Children
Dr. David Ho of Columbia University emphasizes the importance of staying up to date on Covid shots, as the updated vaccine aligns with the virus’s changes. However, he acknowledges the ongoing challenge of keeping pace with the virus, stating that scientists are continually playing catch-up in the battle against Covid.